Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Editas Medicine 11 Hurley Street Cambridge MA 02141 USA

www.editasmedicine.com P: 617-401-9000

Description:

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target several disease areas, ocular diseases and engineered cell medicines are two such zones where its pipeline is most mature.

Key Statistics

Overview:

Market Capitalization, $K 451,487
Enterprise Value, $K 327,837
Shares Outstanding, K 82,238
Annual Sales, $ 78,120 K
Annual Net Income, $ -153,220 K
Last Quarter Sales, $ 1,140 K
Last Quarter Net Income, $ -61,950 K
EBIT, $ -185,200 K
EBITDA, $ -183,960 K
60-Month Beta 2.06
% of Insider Shareholders 1.90%
% of Institutional Shareholders 71.90%
Float, K 80,675
% Float 98.10%
Short Volume Ratio 0.64

Growth:

1-Year Return -54.37%
3-Year Return -84.70%
5-Year Return -75.95%
5-Year Revenue Growth 144.58%
5-Year Earnings Growth 13.30%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.76 on 05/08/24
Next Earnings Date 08/07/24
Earnings Per Share ttm -2.10
EPS Growth vs. Prev Qtr -230.43%
EPS Growth vs. Prev Year -7.04%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

EDIT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -47.34%
Return-on-Assets % -33.46%
Profit Margin % -196.13%
Debt/Equity 0.00
Price/Sales 6.36
Price/Cash Flow N/A
Price/Book 1.69
Book Value/Share 3.58
Interest Coverage -1.20
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar